Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.

[1]  Maurie Markman,et al.  Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. , 2005, Gynecologic oncology.

[2]  M. Markman,et al.  Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn. , 2004, Gynecologic oncology.

[3]  F. Dosio,et al.  From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy , 2003, Tumori.

[4]  Theresa M Allen,et al.  Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. , 2003, Biochimica et biophysica acta.

[5]  A Ingber,et al.  Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. , 2000, Archives of dermatology.

[6]  D. Tzemach,et al.  Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma , 2000, Cancer.

[7]  M. Sehested,et al.  Treatment of anthracycline extravasation with dexrazoxane. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Lokich.  Five-year leukemia survival by age. , 1999 .

[9]  D. Northfelt,et al.  Lack of vesicant injury following extravasation of liposomal doxorubicin. , 1995, Journal of the National Cancer Institute.

[10]  J. Cassady,et al.  Radiation‐adriamycin interactions: Preliminary clinical observations , 1975, Cancer.